{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["Siwatch S"],"pubmed_abstract":["<h4>Introduction</h4>Acute fatty liver of pregnancy (AFLP) is a fatal disease occurring in 3rd trimester. The safety and efficacy of plasmapheresis/plasma exchange (PP/PE) as an adjunctive treatment in patients of AFLP has been studied. We performed systematic review and meta-analysis to estimate the clinical parameters that included mortality rates and improvement of the biochemical parameters including Liver and Renal function enzymes, coagulopathy factors of AFLP patients.<h4>Methods</h4>We searched PubMed, Ovid MEDLINE, Cochrane, CINAHL and Scopus, ClinicalTrials.gov. RevMan statistical software was used for meta-analysis.<h4>Results</h4>Pooled survival proportion for AFLP patients treated with PP/PE was 87.74% (95% CI: 82.84 to 91.65). Efficacy of PP/PE was studied by its effect on mo"],"journal":["Frontiers in medicine"],"pagination":["1433324"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11527697"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of plasmapheresis in treatment of acute fatty liver of pregnancy-a systematic review and meta-analysis."],"pmcid":["PMC11527697"],"pubmed_authors":["De A","Siwatch S","Periyasamy AG","Kaur B","Lamba DS","Kaur S","Singh V"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of plasmapheresis in treatment of acute fatty liver of pregnancy-a systematic review and meta-analysis.","description":"<h4>Introduction</h4>Acute fatty liver of pregnancy (AFLP) is a fatal disease occurring in 3rd trimester. The safety and efficacy of plasmapheresis/plasma exchange (PP/PE) as an adjunctive treatment in patients of AFLP has been studied. We performed systematic review and meta-analysis to estimate the clinical parameters that included mortality rates and improvement of the biochemical parameters including Liver and Renal function enzymes, coagulopathy factors of AFLP patients.<h4>Methods</h4>We searched PubMed, Ovid MEDLINE, Cochrane, CINAHL and Scopus, ClinicalTrials.gov. RevMan statistical software was used for meta-analysis.<h4>Results</h4>Pooled survival proportion for AFLP patients treated with PP/PE was 87.74% (95% CI: 82.84 to 91.65). Efficacy of PP/PE was studied by its effect on mo","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-07-16T09:34:35.839Z","creation":"2025-04-04T13:20:01.676Z"},"accession":"S-EPMC11527697","cross_references":{"pubmed":["39493711"],"doi":["10.3389/fmed.2024.1433324"]}}